DSM has issued preliminary results for Q1 2018, ahead of the scheduled Q1 results announcement on 8 May 2018. The company says it saw continued strong organic sales growth in underlying business, estimated at 11%, with adjusted EBITDA growth of underlying business estimated at 7% despite significant FX headwind.

Feike Sijbesma, CEO/Chairman DSM Managing Board, said: “We are very pleased that the strong underlying performance of our business continues, with growth well above market. In addition, we are currently benefitting from substantially higher prices in some vitamins due to exceptional supply disruptions in the industry, which are expected to be temporary and heavily weighted towards the first half of the year. These two combined result in a significantly higher outlook for the full year 2018.”